Business Context and Reporting Period
This Form 8-K is a current report filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on August 22, 2022. The registrant is a Delaware corporation with principal executive offices in Palo Alto, California. The company is classified as an emerging growth company and its common stock and warrants trade on The NASDAQ Stock Market LLC under the symbols ATNF and ATNFW, respectively.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding a clinical trial milestone and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the enrollment of the first patient in a clinical trial supported by the Company. The trial, conducted by the University of Oxford, evaluates an anti-tumor necrosis factor (TNF) therapy for people with early-stage frozen shoulder.
Guidance, Outlook, and Risks
- Management Commentary: The press release furnished as Exhibit 99.1 contains forward-looking statements regarding the Company's expectations for the trial and future performance.
- Risks and Uncertainties: The filing explicitly states that actual events and results may differ materially from projected statements due to known and unknown risks. These risks include factors outside the Company's control that could affect financial results and business trends.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the specific details of the University of Oxford trial protocol and the anti-TNF therapy mechanism in the press release (Exhibit 99.1).
- Review the Company's most recent Form 10-Q or 10-K for actual financial performance, cash runway, and liquidity status, as this 8-K contains no financial data.
- Assess the "Risk Factors" section in periodic filings to understand potential obstacles to the trial's success or commercialization.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.